Episodes

  • ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders

    ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders
    Nov 3 2025

    Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer.

    CME information and select publications here.

    Show More Show Less
    41 mins
  • Colorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease Analysis

    Colorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease Analysis
    Oct 29 2025

    Dr John Strickler from Duke University in Durham, North Carolina, discusses the measurement of molecular residual disease and its current and potential role in colorectal cancer risk assessment, surveillance and treatment decision-making.

    CME information and select publications here.

    Show More Show Less
    51 mins
  • Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates

    Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates
    Oct 20 2025

    Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer.

    CME information and select publications here.

    Show More Show Less
    57 mins
  • Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

    Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    Oct 24 2025

    Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer.

    CME information and select publications here.

    Show More Show Less
    16 mins
  • Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA

    Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA
    Oct 22 2025

    Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia.

    CME information and select publications here.

    Show More Show Less
    55 mins
  • Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

    Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    Oct 18 2025

    Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.

    CME information and select publications here.

    Show More Show Less
    25 mins
  • Non-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease Management

    Non-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease Management
    Oct 17 2025

    Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma.

    CME information and select publications here.

    Show More Show Less
    58 mins
  • HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment

    HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
    Oct 13 2025

    Dr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and future management of HR-positive and triple-negative metastatic breast cancer.

    CME information and select publications here.

    Show More Show Less
    44 mins